Hepatitis B Patent Ruling 'Infected,' BMS Tells Fed. Circ.
Bristol-Myers Squibb Co. on Monday urged the Federal Circuit to reverse a decision that invalidated its patent covering the hepatitis B drug Baraclude, arguing that the district court relied on faulty...To view the full article, register now.
Already a subscriber? Click here to view full article